Does ruxolitinib prolong the survival of patients with myelofibrosis?
F Cervantes, A Pereira - Blood, The Journal of the American …, 2017 - ashpublications.org
F Cervantes, A Pereira
Blood, The Journal of the American Society of Hematology, 2017•ashpublications.orgA 73-year-old man was diagnosed with primary myelofibrosis (PMF) after the incidental
discovery of abnormalities in a blood test performed for the control of diabetes mellitus. The
patient was asymptomatic. The spleen was palpable at 6 cm below the left costal margin.
Hemoglobin was 10.9 g/dL; white blood cell count was 13.2 3 109/L, with a
leukoerythroblastic blood picture and 2% blasts, platelet count of 3873 109/L, and serum
lactic dehydrogenase level of 1087 U/L. BCR/ABL was negative, and the JAK2 V617F …
discovery of abnormalities in a blood test performed for the control of diabetes mellitus. The
patient was asymptomatic. The spleen was palpable at 6 cm below the left costal margin.
Hemoglobin was 10.9 g/dL; white blood cell count was 13.2 3 109/L, with a
leukoerythroblastic blood picture and 2% blasts, platelet count of 3873 109/L, and serum
lactic dehydrogenase level of 1087 U/L. BCR/ABL was negative, and the JAK2 V617F …
A 73-year-old man was diagnosed with primary myelofibrosis (PMF) after the incidental discovery of abnormalities in a blood test performed for the control of diabetes mellitus. The patient was asymptomatic. The spleen was palpable at 6 cm below the left costal margin. Hemoglobin was 10.9 g/dL; white blood cell count was 13.2 3 109/L, with a leukoerythroblastic blood picture and 2% blasts, platelet count of 3873 109/L, and serum lactic dehydrogenase level of 1087 U/L. BCR/ABL was negative, and the JAK2 V617F mutation was found. Bone marrow cytogenetic study disclosed a normal 46, XY karyotype, and the marrow biopsy was typical of myelofibrosis. According to the International Prognostic Scoring System (IPSS), 1 the patient had intermediate-2 risk PMF, because of age over 65 years and blood blasts $1%. Median survival of patients with intermediate-2 risk PMF is 4 years. Because the patient was asymptomatic and not eligible for allogeneic stem cell transplantation, should he receive ruxolitinib to try to prolong his survival?
ashpublications.org